Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta Expands Portfolio, TMC Narrows Focus To LDL Reduction With Anti-Infective Deal

Executive Summary

A transaction bringing newly public Melinta three anti-infective products and a related sales force from The Medicines Co. will enable the latter to downsize and focus on its Phase III PCSK9 inhibitor inclisiran.

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
Quiet Riot? Gene Silencing Candidates Still Ready To Make Noise In Lipid Disorders
Melinta: A Pure-Play Antibiotics Specialist Rises
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim
Medicines Company Gets Aggressive With Inclisiran Phase III Plans
Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela
Melinta To Launch First Commercial Drug Baxdela Independently

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel